These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 940296)

  • 1. Control of mineralocorticoid substitution in Addison's disease by plasma renin measurement.
    Oelkers W; L'age M
    Klin Wochenschr; 1976 Jul; 54(13):607-12. PubMed ID: 940296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of fludrocortisone withdrawal on plasma angiotensin II, ACTH, vasopressin, and potassium in patients with Addison's disease.
    Oelkers W; Bähr V
    Acta Endocrinol (Copenh); 1987 Jul; 115(3):325-30. PubMed ID: 3039766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mineralocorticoid replacement in Addison's disease.
    Thompson DG; Mason AS; Goodwin FJ
    Clin Endocrinol (Oxf); 1979 May; 10(5):499-506. PubMed ID: 476980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atrial natriuretic peptide and plasma renin levels in assessment of mineralocorticoid replacement in Addison's disease.
    Cohen N; Gilbert R; Wirth A; Casley D; Jerums G
    J Clin Endocrinol Metab; 1996 Apr; 81(4):1411-5. PubMed ID: 8636343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnosis and therapy surveillance in Addison's disease: rapid adrenocorticotropin (ACTH) test and measurement of plasma ACTH, renin activity, and aldosterone.
    Oelkers W; Diederich S; Bähr V
    J Clin Endocrinol Metab; 1992 Jul; 75(1):259-64. PubMed ID: 1320051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of plasma renin activity to monitor mineralocorticoid treatment in dogs with primary hypoadrenocorticism: desoxycorticosterone versus fludrocortisone.
    Baumstark ME; Nussberger J; Boretti FS; Baumstark MW; Riond B; Reusch CE; Sieber-Ruckstuhl NS
    J Vet Intern Med; 2014; 28(5):1471-8. PubMed ID: 25274440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of plasma renin activity in evaluating the adequacy of mineralocorticoid replacement in primary adrenal insufficiency.
    Flad TM; Conway JD; Cunningham SK; McKenna TJ
    Clin Endocrinol (Oxf); 1996 Nov; 45(5):529-34. PubMed ID: 8977748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Proceedings: Plasma renin activity in management of Addison's disease (author's transl)].
    Linquette M; Lefebvre J; Fossati P; Fourlinnie JC; Cappoen JP; Lecieux P
    Ann Endocrinol (Paris); 1975; 36(2):103-4. PubMed ID: 1190719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence that patients with Addison's disease are undertreated with fludrocortisone.
    Smith SJ; MacGregor GA; Markandu ND; Bayliss J; Banks RA; Prentice MG; Dorrington-Ward P; Wise P
    Lancet; 1984 Jan; 1(8367):11-4. PubMed ID: 6140341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes of plasma renin, angiotensin II and renin substrate during reversal of malignant renovascular hypertension.
    Schultze G; Oelkers W
    Klin Wochenschr; 1975 Dec; 53(23):1115-9. PubMed ID: 1206969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mineralocorticoid substitution and monitoring in primary adrenal insufficiency.
    Quinkler M; Oelkers W; Remde H; Allolio B
    Best Pract Res Clin Endocrinol Metab; 2015 Jan; 29(1):17-24. PubMed ID: 25617169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mineralocorticoids in the management of primary adrenocortical insufficiency.
    Jadoul M; Ferrant A; De Plaen JF; Crabbé J
    J Endocrinol Invest; 1991 Feb; 14(2):87-91. PubMed ID: 2061574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renin, renin substrate and angiotensin II concentration in renal venous blood.
    Oelkers W; Holze C; Molzahn M; Soerensen R
    Contrib Nephrol; 1976; 3():150-9. PubMed ID: 1026364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of conjugated estrogens on the renin-angiotensin system.
    Pallas KG; Holzwarth GJ; Stern MP; Lucas CP
    J Clin Endocrinol Metab; 1977 Jun; 44(6):1061-8. PubMed ID: 194909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of hypertension and heart failure in patients with Addison's disease.
    Inder WJ; Meyer C; Hunt PJ
    Clin Endocrinol (Oxf); 2015 Jun; 82(6):789-92. PubMed ID: 25138826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renin, angiotensin, corticosteroids, and electrolyte balance in Addison's disease.
    Brown JJ; Fraser R; Lever AF; Robertson JI; James VH; McCusker J; Wynn V
    Q J Med; 1968 Jan; 37(145):97-118. PubMed ID: 4297956
    [No Abstract]   [Full Text] [Related]  

  • 17. [Metabolic assessment of hydrocortisone replacement therapy in patients with primary adrenocortical insufficiency].
    Fichna M; Gryczyńska M; Sowińska A; Sowiński J
    Przegl Lek; 2011; 68(2):96-102. PubMed ID: 21751518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pharmacological action of 9alpha-fluorohydrocortisone as a mineralocorticoid].
    Sekihara H
    Nihon Rinsho; 1994 Mar; 52(3):583-6. PubMed ID: 8164353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Replacement therapy for Addison's disease: recent developments.
    Løvås K; Husebye ES
    Expert Opin Investig Drugs; 2008 Apr; 17(4):497-509. PubMed ID: 18363515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating levels of adrenomedullin in patients with Addison's disease before and after corticosteroid treatment.
    Letizia C; Cerci S; Centanni M; De Toma G; Subioli S; Scuro L; Scavo D
    Clin Endocrinol (Oxf); 1998 Feb; 48(2):145-8. PubMed ID: 9579224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.